Alzamend Neuro, Inc. (NASDAQ:ALZN) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on March 11, 2026.
The Healthcare company reported Q0 revenue of .
Alzamend Neuro, Inc.'s stock currently trades at $2.18 with a market capitalization of $6.3M.
The 10-Q provides Alzamend Neuro, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Alzamend Neuro, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.